Cesare Selli
YOU?
Author Swipe
View article: Intraductal prostate cancer: An aggressive subset of prostate cancers? Immunophenotypic evaluation
Intraductal prostate cancer: An aggressive subset of prostate cancers? Immunophenotypic evaluation Open
The relationship to tumor phenotype and prognosis was more considerable in ERG-positive tumors than in ERG-negative tumors. EZH2 has gained great interest as a target for epigenetic cancer therapy. Although prostate cancer is a hypoxic tum…
View article: Robotically assisted removal of pelvic splenosis fifty-six years after splenectomy: A case report
Robotically assisted removal of pelvic splenosis fifty-six years after splenectomy: A case report Open
In a patient requiring differential diagnosis of splenosis nodules from lymphoma recurrence, the robotic approach provided a safe en bloc removal with short hospitalization. The Da Vinci Xi robot was particularly helpful because its optics…
View article: p16 and its putative interplay with metabolic factors in prostate cancer: An analysis based on public TCGA data
p16 and its putative interplay with metabolic factors in prostate cancer: An analysis based on public TCGA data Open
p16 is one of the most common tumour suppressor genes, mainly due to its genetic inactivation. However, the clinical significance of p16 in prostate cancer is not yet fully understood, and although p16 acts as a tumour suppressor gene, str…
View article: A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New <i>RET</i> Germline Deletion
A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New <i>RET</i> Germline Deletion Open
Background . Multiple endocrine neoplasia type 2 (MEN2) is a hereditary cancer syndrome caused by RET proto‐oncogene mutation. Two different clinical variants of MEN2 are known (MEN2A and MEN2B): medullary thyroid carcinoma (MTC) almost al…
View article: Primary small cell carcinoma of the ureter
Primary small cell carcinoma of the ureter Open
The clinicians must be aware of this aggressive tumor with silent clinical course and advanced stages at presentation.